Citadel Advisors
PPBT

Citadel Advisors’s Purple Biotech PPBT Stock Holding History

Citadel Advisors’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,750
Closed -$31.2K – 13953
2025
Q4 		$31.2K Buy
+4,750
New +$34.5K ﹤0.01% 12216
2023
Q4 		– Sell
-8
Closed -$1.73K – 15017
2023
Q3 		$1.73K Sell
8
-10
-56% -$2.38K ﹤0.01% 13818
2023
Q2 		$4.9K Sell
18
-3
-14% -$1.08K ﹤0.01% 13552
2023
Q1 		$7.39K Buy
21
+12
+133% +$4.5K ﹤0.01% 13731
2022
Q4 		$2.35K Buy
+9
New +$3.45K ﹤0.01% 14348
2022
Q2 		– Sell
-85
Closed -$67K – 13824
2022
Q1 		$67K Sell
85
-88
-51% -$56.8K ﹤0.01% 12607
2021
Q4 		$134K Sell
173
-1
-0.6% -$852 ﹤0.01% 12409
2021
Q3 		$159K Sell
174
-108
-38% -$105K ﹤0.01% 12297
2021
Q2 		$275K Buy
+282
New +$259K ﹤0.01% 11475

Other funds holding PPBT

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $240M AUM
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Citadel Advisors's PPBT Position: Q1 2026 in Review

Citadel Advisors sold out of Purple Biotech (PPBT) in Q1 2026, closing a stake of 4,274 shares — an estimated $28.1K sold.

Citadel Advisors first reported a position in PPBT in Q2 2016 and held it in 17 quarters. The position peaked at $400K in Q2 2020. 15 funds tracked by Wall St. Rank hold PPBT as of Q1 2026.

  • Citadel Advisors reported no remaining Purple Biotech position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 4,274 Purple Biotech shares in Q1 2026, an estimated $28.1K.
  • Citadel Advisors first reported a position in Purple Biotech in Q2 2016 and held it in 17 quarters.
  • Citadel Advisors's Purple Biotech position peaked at $400K in Q2 2020.
  • 15 funds tracked by Wall St. Rank held Purple Biotech as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.